J&J succeeds in trial for drug delivery system (JNJ:NYSE)

Johnson & Johnson (JNJ) announced positive results from a Phase 1 trial for a novel drug delivery system. This system is designed to administer its bladder cancer therapy, erdafitinib, which was developed in collaboration with Otsuka (OTSKY) (OTSKF). The trial successfully met its primary safety endpoint.